2021
Outcomes in patients with anthracycline‐induced cardiomyopathy undergoing left ventricular assist devices implantation
Guha A, Caraballo C, Jain P, Miller PE, Owusu‐Guha J, Clark KAA, Velazquez EJ, Ahmad T, Baldassarre LA, Addison D, Weintraub NL, Desai NR. Outcomes in patients with anthracycline‐induced cardiomyopathy undergoing left ventricular assist devices implantation. ESC Heart Failure 2021, 8: 2866-2875. PMID: 33982867, PMCID: PMC8318466, DOI: 10.1002/ehf2.13362.Peer-Reviewed Original ResearchConceptsAnthracycline-induced cardiomyopathyIschemic cardiomyopathyCardiomyopathy patientsCF-LVADICM patientsLeft ventricular assist device implantationContinuous-flow LVAD implantationHigher major bleeding riskVentricular assist device implantationEnd-stage heart failureMechanically Assisted Circulatory SupportCox proportional hazards modelCF-LVAD implantationAcute kidney injuryMajor bleeding riskAssist device implantationEtiology of cardiomyopathyProportional hazards modelBleeding riskKidney injuryInteragency RegistryLVAD implantationMajor infectionMedian survivalRespiratory support
2020
Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation
Higgins AY, Bjerre J, Parzynski CS, Minges KE, Ahmad T, Desai NR, Enriquez A, Spatz ES, Friedman DJ, Curtis JP, Hlatky MA, Freeman JV. Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation. The American Journal Of Cardiology 2020, 133: 116-125. PMID: 32862971, DOI: 10.1016/j.amjcard.2020.07.035.Peer-Reviewed Original ResearchConceptsNon-ischemic cardiomyopathyImplantable cardioverter defibrillator implantationCardioverter-defibrillator implantationICM patientsIschemic cardiomyopathyNational Cardiovascular Data Registry ICD RegistryCox proportional hazards regression modelPrimary prevention ICD implantationLeft ventricular ejection fractionProportional hazards regression modelsPrimary prevention ICDsRetrospective cohort studyVentricular ejection fractionKaplan-Meier curvesHazards regression modelsRisk of mortalityComparison of mortalityMedian followCohort studyICD implantationEjection fractionHeart failureHospital readmissionICD RegistryPatient subgroups
2015
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C
Ahmad T, Yin P, Saffitz J, Pockros PJ, Lalezari J, Shiffman M, Freilich B, Zamparo J, Brown K, Dimitrova D, Kumar M, Manion D, Heath-Chiozzi M, Wolf R, Hughes E, Muir AJ, Hernandez AF. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology 2015, 62: 409-416. PMID: 25251156, DOI: 10.1002/hep.27488.Peer-Reviewed Original ResearchConceptsNucleotide polymerase inhibitorLVEF dysfunctionPolymerase inhibitorsB-type natriuretic peptide levelsChronic hepatitis C virus (HCV) infectionHepatitis C virus infectionActing antiviral (DAA) agentsSevere myocyte damageC virus infectionNatriuretic peptide levelsPhase II studyVentricular ejection fractionT-wave inversionOff-target toxicityHCV treatmentHepatitis CII studySystolic functionTransthoracic echocardiogramEjection fractionNew DAAsCardiac dysfunctionElectrocardiogram changesPathological findingsCardiac toxicity